Browne L Daniel 4
4 · Revance Therapeutics, Inc. · Filed Jan 3, 2018
Insider Transaction Report
Form 4
Browne L Daniel
DirectorCEO and President
Transactions
- Other
Common Stock
2017-12-29$22.99/sh+127$2,920→ 133,315 total
Holdings
- 409(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]These shares were acquired by Mr. Browne under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 29, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mr. Browne purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2017.
- [F2]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.